Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-04-03 16:01:09 ET · period of report 2026-04-01 · accession 0001104659-26-039613 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-04-03 16:01 | 2026-04-01 | REGN | RYAN ARTHUR F | Dir | S - Sale | $777.27 | -100 | 17.6K | -0.6% | -$77.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | S | D | 1 | $771.32 | 17,702 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. |
| 2 | Common | Common Stock | 2026-04-01 | S | D | 3 | $772.76 | 17,699 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F2) Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2026 at prices ranging from $772.62 to $772.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 3 | Common | Common Stock | 2026-04-01 | S | D | 8 | $773.59 | 17,691 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F3) Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $773.27 to $773.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 4 | Common | Common Stock | 2026-04-01 | S | D | 8 | $774.58 | 17,683 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F4) Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $774.05 to $774.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 5 | Common | Common Stock | 2026-04-01 | S | D | 14 | $775.58 | 17,669 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F5) Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2026 at prices ranging from $775.04 to $775.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 6 | Common | Common Stock | 2026-04-01 | S | D | 13 | $776.62 | 17,656 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F6) Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2026 at prices ranging from $776.11 to $776.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 7 | Common | Common Stock | 2026-04-01 | S | D | 9 | $777.42 | 17,647 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F7) Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2026 at prices ranging from $777.03 to $777.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 8 | Common | Common Stock | 2026-04-01 | S | D | 4 | $778.24 | 17,643 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F8) Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2026 at prices ranging from $778.02 to $778.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |
| 9 | Common | Common Stock | 2026-04-01 | S | D | 40 | $779.71 | 17,603 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. (F9) Represents volume-weighted average price of sales of 40 shares of Company stock on April 1, 2026 at prices ranging from $779.65 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. |